3.39
3.39 (-0.40%)
As of Dec 12, 2023
Miromatrix Medical Inc. [MIRO]
Source:
Company Overview
We are a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients lives.Founded in 2009, we are one of a small group of companies at the forefront of developing alternatives to human-donor organ transplants, and within this small group of companies there are important differences between the technologies being developed.
| Country | United States |
| Headquarters | eden prairie, minnesota |
| Phone Number | (612)202-7026 |
| Industry | |
| CEO | Jeffrey Ross |
| Website | www.transplant-observatory.org/summary |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-6.6 |
| Net Income | $-6.5 |
| Net Cash | $0.9 |
Profit Ratios
| Gross Margin | $-0.1 |
| Operating Margin | -59,369.1 |
| Profit as % of Revenues | -1,018.5% |
| Profit as % of Assets | -22.2% |
| Profit as % of Stockholder Equity | -41.5% |
Management Effectiveness
| Return on Equity | -41.5% |
| Return on Assets | -27.6% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $23.4 |
| Total Liabilities | $7.9 |
| Operating Cash Flow | $-18.3 |
| Investing Cash Flow | $10.2 |
| Financing Cash Flow | $8.9 |
